Loading clinical trials...
Loading clinical trials...
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD Background: a Dual Arm, Multicenter, Randomized Controlled Study
Conditions
Interventions
Sequential treatment of bevacizumab combined with atezolizumab (sequential group)
Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)
Locations
1
China
Eastern Hepatobiliary Surgery Hospital
Shanghai, Shanghai Municipality, China
Start Date
October 20, 2025
Primary Completion Date
August 30, 2026
Completion Date
August 30, 2026
Last Updated
December 16, 2025
NCT07106827
NCT06999837
NCT07141056
NCT07132515
NCT06999707
NCT06883539
Lead Sponsor
Eastern Hepatobiliary Surgery Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions